Prospective, observational, non-interventional, multicenter real-world evidence study on effectiveness and safety of treatment of patients with moderate to severe Chronic Hand Eczema with delgocitinib cream (20mg/g) (REACHED)

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Other
• If ‘other’, further details on the scope of the study:
  Efficacy and safety study with no comparator
• Data collection methods:
  Primary data collection

Study drug and medical condition

• Name of medicine:
  ANZUPGO
• Study drug International non-proprietary name (INN) or common name:
  DELGOCITINIB
• Anatomical Therapeutic Chemical (ATC) code:
  (D11AH11) delgocitinib

  delgocitinib
• Additional medical condition(s):
  Chronic Hand Eczema (CHE)

Population studied

• Short description of the study population:
  Patients with moderate to severe CHE eligible for treatment with delgocitinib cream as per physicians discretion and for whom the decision for treatment with delgocitinib cream was made prior to inclusion.
• Age groups:
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)
    • Elderly (≥ 65 years)
• Estimated number of subjects:
  500

Study design details

• Study design:
  A single-country, non-interventional, multicenter, non-comparative, prospective, 52-week observational cohort study based on primary data collection.
• Main study objective:
  The research question is to describe the effectiveness, safety profile, and usage of delgocitinib cream in routine clinical practice in Germany over a 52-week observation period.